Selected article for: "clathrin heavy chain and heavy chain"

Author: Bayati, Armin; Kumar, Rahul; Francis, Vincent; McPherson, Peter S.
Title: SARS-CoV-2 infects cells following viral entry via clathrin-mediated endocytosis
  • Cord-id: jb9dme59
  • Document date: 2021_1_19
  • ID: jb9dme59
    Snippet: SARS-CoV-2 is the causative agent of COVID-19, so understanding its biology and infection mechanisms is critical to facing this major medical challenge. SARS-CoV-2 is known to use its spike glycoprotein to interact with the cell surface as a first step in the infection process. As for other coronaviruses, it is likely that SARS-CoV-2 next undergoes endocytosis, but whether or not this is required for infectivity, and the precise endocytic mechanism used are unknown. Using purified spike glycopro
    Document: SARS-CoV-2 is the causative agent of COVID-19, so understanding its biology and infection mechanisms is critical to facing this major medical challenge. SARS-CoV-2 is known to use its spike glycoprotein to interact with the cell surface as a first step in the infection process. As for other coronaviruses, it is likely that SARS-CoV-2 next undergoes endocytosis, but whether or not this is required for infectivity, and the precise endocytic mechanism used are unknown. Using purified spike glycoprotein and lentivirus pseudotyped with spike glycoprotein, a common model of SARS-CoV-2 infectivity, we now demonstrate that following engagement with the plasma membrane, SARS-CoV-2 undergoes rapid, clathrin-mediated endocytosis. This suggests that transfer of viral RNA to the cell cytosol occurs from the lumen of the endosomal system. Importantly, we further demonstrate that knockdown of clathrin-heavy chain, which blocks clathrin-mediated endocytosis, reduces viral infectivity. These discoveries reveal that SARS-CoV-2 uses clathrin-mediated endocytosis to gain access into cells and suggests that this process is a key aspect of virus infectivity.

    Search related documents:
    Co phrase search for related documents
    • abundant expression and low density: 1
    • acute sars cov respiratory syndrome coronavirus and adaptor protein: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and low density: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute sars cov respiratory syndrome coronavirus and low density lipoprotein receptor: 1
    • acute sars cov respiratory syndrome coronavirus and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adaptor protein and low density: 1
    • adaptor protein and low density lipoprotein receptor: 1